Absci Corp (ABSI) research
Absci Corp- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $9.65
- As of
Absci Corp (ABSI): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-11.
As of . Source: SEC EDGAR filings for ABSI. Method and limitations.
Share the ABSI intelligence card
See ABSI live in the terminal
Track ABSI's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live ABSI terminal, freeActive signals for ABSI
- highCONSENSUS_BUY
5 tracked funds increased ABSI this 2026Q2, institutional consensus
- highCONSENSUS_BUY
4 tracked funds increased ABSI this 2026Q2, institutional consensus
- mediumNEW_POSITION
Point72 Asset Management, L.P. new position in ABSI
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 79% of ABSI (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1224% to ABSI (2026Q2)
FREE, NO ACCOUNT
Every signal on ABSI, as it fires
You are seeing 5 of 39 signals recorded on ABSI since 2026-05-16.
The five above landed across 2 days. The other 34 were recorded on 5 other days. 28 of the 39 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ABSI (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 00091E109 · 2026Q2 | $63.7M | 0.05% | , |
| D. E. Shaw & Co., Inc.CUSIP 00091E109 · 2026Q2 | $60.7M | 0.03% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 00091E109 · 2026Q2 | $2.9M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 00091E109 · 2026Q2 | $2.6M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 00091E109 · 2026Q2 | $1.2M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ABSI
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ABSI against its peers
ABSI's return on equity of -60.8% ranks in the 23rd percentile of 10 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | ABSI | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 2.8M USD | n/a | n/a | 4 |
| Operating margin | -4297.0% | n/a | n/a | 4 |
| Net margin | -4113.7% | n/a | n/a | 4 |
| Return on equity | -60.8% | -47.2% | 23 | 10 |
Peers (13): AVBP, LBRX, MAZE, IMTX, BCAX, DRTS, VOR, CGEM, RARE, ORIC, INBX, MGTX, REPL. Left out: AVLN (no annual filing), LTGO (no annual filing), KALV (no annual filing), TRAX (no annual filing), AKTS (no annual filing), AAPG (period gap), SPTX (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (ABSI: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ABSI signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ABSIand get the insider, 13F, options, and confluence read in one view.